[Substance use disorders and ADHD: an overview of recent Dutch research].
Tijdschr Psychiatr. 2013;55(11):861-6
Authors: van Emmerik-van Oortmerssen K, Crunelle CL, Carpentier PJ
Abstract
UNLABELLED: <span class=”abbreviation”>
BACKGROUND: adhd</span> is an important risk factor for the development of substance use disorders (<span class=”abbreviation”>sud</span>).
AIM: To provide an overview of recent Dutch research into the prevalence of <span class=”abbreviation”>adhd</span> in <span class=”abbreviation”>sud</span> populations and the neurobiological substrate of the reduced effect of pharmacological treatment of this patient group.
METHOD: We describe three studies: a meta-analysis and meta-regression analysis of the prevalence of <span class=”abbreviation”>adhd</span> in 6689 <span class=”abbreviation”>sud</span> patients; a cross-sectional study of the prevalence of <span class=”abbreviation”>adhd</span> and several other psychiatric disorders in 193 methadon maintenance patients, and finally a study in which the availability and occupation of dopamine transporters before and after methylphenidate treatment were measured using <span class=”abbreviation”>spect</span> scans in 24 <span class=”abbreviation”>adhd</span> patients with and without cocaine addiction.
RESULTS: The prevalence of <span class=”abbreviation”>adhd</span> in <span class=”abbreviation”>sud</span> patients is estimated to be 23.1% (95% confidence interval 19.4-27.2). This prevalence is influenced by the diagnostic instrument for <span class=”abbreviation”>adhd</span> and by the substance of abuse: cocaine is associated with a lower <span class=”abbreviation”>adhd</span> prevalence than other substances. The prevalence found among methadone maintenance patients was similar, namely 24.9%; additional comorbid psychiatric disorders were also frequently present. In the imaging study, lower availability of dopamine transporters and lower occupation by methylphenidate were found in cocaine-dependent <span class=”abbreviation”>adhd</span> patients than in <span class=”abbreviation”>adhd</span> patients without <span class=”abbreviation”>sud</span>.
CONCLUSION: These studies confirm the high prevalence of <span class=”abbreviation”>adhd</span> in <span class=”abbreviation”>sud</span> patients, and provide a possible explanation for the reduced efficacy of methylphenidate in this patient population.
PMID: 24242145 [PubMed – in process]
via http://www.ncbi.nlm.nih.gov/pubmed/24242145?dopt=Abstract
